In patients with HER2+ de novo metastatic breast cancer who have a clinical complete response in the metastatic sites from chemotherapy + HER2-directed therapy and whose PET scan is negative, but who have breast-only residual disease, surgery can be considered at the site of the primary tumour to obtain no evidence of disease (NED) (REAL Alliance Expert opinion). Here, ERBB2 is linked to neoplasm.